T
Toshiyuki Kozuki
Researcher at Okayama University
Publications - 125
Citations - 4052
Toshiyuki Kozuki is an academic researcher from Okayama University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 24, co-authored 108 publications receiving 3052 citations. Previous affiliations of Toshiyuki Kozuki include Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida,Hiroshi Nokihara,Masashi Kondo,Young Hak Kim,Koichi Azuma,Takashi Seto,Yuichi Takiguchi,Makoto Nishio,Hiroshige Yoshioka,Fumio Imamura,Katsuyuki Hotta,Satoshi Watanabe,Koichi Goto,Miyako Satouchi,Toshiyuki Kozuki,Takehito Shukuya,Kazuhiko Nakagawa,Tetsuya Mitsudomi,Nobuyuki Yamamoto,Takashi Asakawa,Ryoichi Asabe,Tomohiro Tanaka,Tomohide Tamura +22 more
TL;DR: These results provide the first head-to-head comparison of alectinib and crizotinib and have the potential to change the standard of care for the first-line treatment of ALK-positive non-small-cell lung cancer.
Journal ArticleDOI
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte,Federico Cappuzzo,Ihor Vynnychenko,Daniil Stroyakovskiy,Delvys Rodriguez-Abreu,Maen A. Hussein,Ross A. Soo,Henry J. Conter,Toshiyuki Kozuki,Kuan Chieh Huang,V. Graupner,Shawn W. Sun,Tien Hoang,Helen Jessop,Mark McCleland,Marcus Ballinger,Alan Sandler,Mark A. Socinski +17 more
TL;DR: Adding atezolizumab to platinum-based chemotherapy significantly improved PFS in patients with first-line squamous NSCLC; OS was similar between arms.
Journal ArticleDOI
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
Tomoya Kawaguchi,Masahiko Ando,Kazuhiro Asami,Yoshio Okano,Masaaki Fukuda,Hideyuki Nakagawa,Hidenori Ibata,Toshiyuki Kozuki,Takeo Endo,Atsuhisa Tamura,Mitsuhiro Kamimura,Kazuhiro Sakamoto,Michihiro Yoshimi,Yoshifumi Soejima,Yoshio Tomizawa,Shun-ichi Isa,Minoru Takada,Hideo Saka,Akihito Kubo +18 more
TL;DR: Erlotinib failed to show an improvement in PFS or OS compared with docetaxel in an EGFR-unselected patient population of patients with advanced non-small-cell lung cancer in an epidermal growth factor receptor (EGFR) -un selected patient population.
Journal Article
Identification of epigenetic aberrant promoter Methylation in serum DNA is useful for early detection of lung cancer
Keiichi Fujiwara,Nobukazu Fujimoto,Masahiro Tabata,Kenji Nishii,Keitaro Matsuo,Katsuyuki Hotta,Toshiyuki Kozuki,Motoi Aoe,Katsuyuki Kiura,Hiroshi Ueoka,Mitsune Tanimoto +10 more
TL;DR: Results suggest that identification of promoter methylation of tumor suppressor genes in serum DNA could be useful for early detection of lung cancer.
Journal ArticleDOI
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
Robert M. Jotte,Federico Cappuzzo,Ihor Vynnychenko,Daniil Stroyakovskiy,Delvys Rodriguez Abreu,Maen A. Hussein,Ross A. Soo,Henry Jacob Conter,Toshiyuki Kozuki,Carlos J Silva,V. Graupner,Shawn W. Sun,Ray S. Lin,Claudia Kelsch,Marcin Kowanetz,Tien Hoang,Alan Sandler,Mark A. Socinski +17 more
TL;DR: The safety profile of atezo + carbo + nab-pac or pac was consistent with the known risks of the individual treatment components; no new safety signals were identified.